Interleukin 17A-secreting T-helper 17 (Th17) cells are pathogenic in inflammatory kidney diseases, but their intrarenal regulation is poorly understood. In order to better define Th17 cell dynamics during interstitial inflammation, we utilized the mouse unilateral ureteral obstruction model to analyze inflammatory cell subtypes by multicolor flow cytometry and cell sorting and by effects on in vitrogenerated Th17 cells. Interleukin 17A expression localized to CCR6 þ CCR4
þ /À CD4 þ T-cells and progressively increased in obstructed kidneys. The number of CCR6 þ CD4 þ T-cells increased over 10-fold by 72 h, were enriched for interleukin 17A production, and were highly proliferative based on in vivo bromodeoxyuridine incorporation. Secreted products of leukocytes isolated from obstructed kidneys enhanced the interleukin 17A production of in vitro-generated Th17 cells. This Th17-enhancing activity was identified as interleukin-1 produced by renal dendritic cells and monocytes. The in vivo validity of these findings was confirmed in mice lacking the interleulin-1 receptor and in mice treated with a recombinant interleukin-1 receptor antagonist, each of which exhibited reduced intrarenal Th17 activity compared with control mice. Thus, the inflamed kidney accumulates CCR6 þ Th17 cells that undergo activation and proliferation. Production of interleukin 1 family cytokines by resident dendritic cells and infiltrating monocytes enhances intrarenal Th17 activation in acute kidney injury. Acute kidney injury (AKI) is characterized by increased interstitial lymphocytes, mononuclear phagocytes, and neutrophils. 1, 2 Obstruction and ischemia represent 30-50% of AKI and frequently progress to chronic kidney disease. [3] [4] [5] During AKI and glomerulonephritis, CD4
þ T-helper (Th) cells participate in renal inflammation and fibrosis. [6] [7] [8] [9] [10] Naïve Th cells differentiate into functionally distinct subsets distinguished by signature effector cytokines. 11, 12 Th type 1 (Th1) cells produce interferon-gamma (IFN-g) and are linked with tissue-destructive inflammation, whereas Th2 cells secrete interleukin (IL)-4, -5, and -13 and, under some conditions, are anti-inflammatory. 11, 12 Recently some disease processes, originally believed to be Th1 mediated, were shown to be partly or predominantly driven by a proinflammatory CD4 þ T-cell subtype, Th17, which is characterized by the production of IL-17 family cytokines. [13] [14] [15] Interleukin-17A, the best characterized and most potent of these, stimulates neutrophil migration to sites of inflammation and amplifies effects of other proinflammatory cytokines on fibroblasts, epithelial, and mesangial cells. 13, 16, 17 IL-17A-producing cells are pathogenic in Crohn's disease, multiple sclerosis, rheumatoid arthritis, 15 glomerulonephritis, 9, 18, 19 and AKI. 20, 21 Th17 cells differ from Th1 and Th2 cells by cytokine profile, chemokine receptor expression, and mechanisms of differentiation and activation. 14 In humans, Th17 cells express CCR2, CCR4, CCR6, and CXCR4, 22, 23 whereas in mouse they preferentially express CCR6, CCR4, and CCR7. 24 Although Th17 cells express some trafficking receptors in a tissue-specific manner, CCR6 appears to be uniformly expressed. 23 Th17 differentiation is incompletely understood but transforming growth factor-b, IL-6, IL-21, and IL-23 are implicated in both humans and mouse. 15, [25] [26] [27] IL-23 promotes the expansion of established Th17 populations but does not induce Th17 differentiation in naïve T-cell precursors. 28 IL-1 family cytokines are also critically required for early Th17 cell programming and for Th17 cell-mediated autoimmunity. 14, 29 In synergy with IL-6 and IL-23, IL-1 regulates Th17 cell differentiation and maintains IL-17A expression in Th17 effectors. 30 IL-1 also regulates activation of previously differentiated (effector memory) Th17 cells during tissue-specific inflammation and autoimmunity 31 -a process that may be of specific relevance to Th17 cell involvement in renal inflammation.
Recently published studies have demonstrated the pathogenic significance of IL-17A-producing cells in diverse renal diseases. 17, 18, 21, [32] [33] [34] [35] [36] [37] [38] [39] Drawing upon our prior observations demonstrating the presence of renal effector memory Th17 cells in mouse unilateral ureteral obstruction (UUO), 20 the present study sought to define molecular species and their cellular sources that underlie the presence of activated Th17 cells in the obstructed kidney, the key phenotypic characteristics of these cells, especially as they relate to inflammatory processes, and the functional significance of the identified pathway accounting for the Th17 cell accumulation in the obstructed kidney.
RESULTS IL-17A is increasingly expressed in the renal cortex following UUO and is localized to CD4 þ T cells
Total leukocytes (CD45-enriched cells), prepared from mouse kidneys at 24, 48, and 72 h following UUO and stimulated with a low concentration of anti-CD3 antibody, produced IL-17A that was of higher concentration from cells of obstructed kidneys compared with non-obstructed (control) kidneys, and increased progressively over time ( Figure 1a ). The largest increment in anti-CD3-inducible IL-17A occurred between 24 and 48 h. Cortical tissue from individual kidneys was subjected to quantitative RT-PCR (qRT-PCR; Figure 1b ), demonstrating a progressive increase in IL-17A mRNA in obstructed kidneys between 24 and 72 h, and confirming in situ IL-17A expression following UUO. Quantitative RT-PCR of magnetic bead-separated CD45 þ and CD45 À cells from kidney digests indicated that IL-17A mRNA was confined to the CD45 þ leukocyte-enriched fractions (Figure 1c) . Fluorescence-activated cell sorting (FACS) of 72-h kidney digests into four individual fractions based on expression of CD45, the Th marker CD4, and the dendritic cell (DC) marker CD11c demonstrated that IL-17A mRNA was localized to the CD4 þ fraction of obstructed kidneys (Figure 1d ). Thus, consistent with our previous findings, 20 a subset of T cells within obstructed but not control kidneys are primed to secrete IL-17A in high amounts following low-level T-cell receptor stimulation. Furthermore, a progressive increase in intrarenal expression of IL-17A occurs within 72 h of UUO and is localized to CD4 þ leukocytes.
Renal Th17 cells preferentially express CCR6 and undergo progressive accumulation and proliferation in obstructed kidneys Chemokine receptor expression was examined as a means to identify T-cell sub-populations enriched for Th17 activity. Combined surface and intracellular staining of anti-CD3-stimulated cells of 72-h obstructed kidney cells was analyzed by multicolor flow cytometry. Cells were surface stained for CD45, CD4, and one of several chemokine receptors (CCR2, CCR4, CCR5, CCR6, CXCR3), and then intracellularly stained for IL-17A (Figure 2a and b) . IL-17A þ CD4 þ cells were most readily distinguishable from IL-17A À
CD4
þ cells by frequency of CCR6 expression (488% versus o9% in this experiment, one of three performed). CCR4 expression was also more frequent on IL- Renal leukocyte populations secrete Th17-activating factors following UUO
As we had previously observed that liposomal clodronate administration before UUO resulted in loss of intrarenal CD4 þ T cell priming for IL-17A production, 20 we hypothesized that intrarenal Th17 cell activity following UUO is promoted by one or more factors produced locally by cells of the mononuclear phagocyte system. To investigate further, conditioned media (CM) were prepared from CD45 To elucidate the contribution of IL-1 to both proliferation and activation of intrarenal Th17 cells in genetically normal animals, groups of mice were administered the recombinant IL-1R1 antagonist (IL-1Ra), anakinra, or vehicle for 72 h post UUO along with continuous in vivo BrdU labeling. IL-1Ra administration did not result in an overall reduction in the proportionate accumulation of CD45 þ leukocytes in obstructed kidneys (Figure 9a ) or in the proportion of intrarenal CD45
þ that were BrdU þ (data not shown). 
Relative quantity (RQ) of IL-17A mRNA in four fluorescence-activated cell sorting (FACS)-purified cell populations from control (CK) and OK 72 h after unilateral ureteral obstruction (UUO):
, and CD45 À (see Supplementary Figure S1 online for illustration of sorting strategy and purity).
Nevertheless, the proportion of CD4 þ T cells among the CD45 þ cells was reduced in obstructed kidneys of IL-1Ra-treated mice-primarily due to reduced proportion of CD4 þ BrdU þ cells (Figure 9b ). Intracellular staining of anti-CD3-stimulated cells from obstructed kidneys demonstrated that, for BrdU þ , but not for BrdU À CD4 þ T cells, IL-1Ra administration was associated with reductions in the proportion that were IL-17A þ , as well in the mean fluorescence intensity of anti-IL-17A staining among the IL-17A þ cells (Figure 9c ). Reduced Th17 activity in obstructed kidneys of IL-1Ra-treated mice was also demonstrated by IL-17A ELISA of anti-CD3-stimulated culture supernatants and by qRT-PCR of renal cortical tissue for IL-17A mRNA (Figure 9d 
Th17-enhancing IL-1 is produced by DCs and monocytes in obstructed kidney
To more clearly identify cellular sources of Th17-enhancing activity following UUO, four individual myeloid cell populations were sorted to high purity by FACS from 72-h obstructed and control kidneys based on surface expression of CD11b, CD11c, F4/80, and Ly6C. These populations were designated as follows:
þ DCs, F4/80 À DCs, and inflammatory monocytes (but not macrophages) from obstructed kidneys with restimulated, in vitro-generated Th17 cells resulted in enhanced IL-17A production ( Figure  10a ). Of interest, CM from total CD45 þ cells and from the sorted myeloid cell sub-populations did not enhance IFN-g production by restimulated in vitro-generated Th1 (Figure 10b and c) . A similar expression pattern was observed for IL-23, whereas IL-6 expression was found to be highest in macrophages purified from the obstructed kidney (Supplementary Figure S10 online). Taken together, the results indicate that IL-1a and/or IL-1b represent important intrarenal Th17-enhancing factors and are produced within the obstructed kidney both by resident (DCs) and infiltrating (monocytes) myeloid cell populations. proliferation in vivo following UUO. As such, our studies provide novel insights regarding the nature of the processes that enable the accumulation and activation of Th17 cells in the injured kidney. In recent years, important roles for Th17 cells, their dominant secreted product, IL-17A, and the factors responsible for their differentiation and activation have been demonstrated in a range of kidney diseases. 18, 19 Increased intrarenal leukocyte expression of IL-17A has been reported in human and rodent transplant rejection, lupus nephritis, and crescentic glomerulonephritis, as well as in human nephrotic syndrome and rodent ischemia-reperfusion injury. 17, 21, [32] [33] [34] [35] [36] 39, 41, 42 Deficiency or blockade of IL-17A ameliorates the severity of kidney disease in rodent models of ischemia-reperfusion injury, nephrotoxic serum nephritis, and anti-myeloperoxidase glomerulonephritis, 17, 21, 37 whereas the presence and/or frequency of intrarenal IL-17-producing lymphocytes correlates with disease severity in human lupus nephritis and chronic transplant rejection. 36, 39 Of interest, this recent literature indicates that the potential cellular sources for pathogenic IL-17A within the À CD8 À (double-negative) T cells, 33, 34 and gd-T cells. 43 Nevertheless, our own prior observations in UUO 20 and those of others in glomerulonephritis 17, 44, 45 and transplant rejection 39 confirm that diverse forms of progressive renal immune/inflammatory disease are associated with interstitial accumulation of bona fide Th17 cells expressing markers of effector memory and activated phenotypes. In the current study, we confirm that UUO produces a progressive increase in IL-17A expression within obstructed renal cortex over 72 h and, using magnetic cell separation and high-level purification by FACS, we sequentially localize IL-17A mRNA to CD45
þ leukocytes, CD4 þ T cells, and, finally, the CCR6 þ CD4 þ T-cell subfraction. The observation indicates a degree of intrinsic activation of Th17 cells, as detectable IL-17A transcript was absent in equivalent fractions from non-obstructed kidneys. Given the presumed non-antigenspecific nature of obstruction-associated inflammatory injury, this finding is in keeping with so-called 'bystander activation' of effector memory Th17 cells, although T-cell receptor specificity for renal autoantigens remains an intriguing possibility. 46, 47 In keeping with the recent findings of Turner et al. 45 in nephrotoxic serum nephritis, we find that intrarenal Th17 cells in UUO are predominantly CCR6
þ .
At 72 h, up to one-third of CD4 þ CCR6 þ cells were capable of rapid IL-17A production upon low-level T-cell receptor stimulation. Notably, the number of CD4 þ CCR6 þ Th cells increased over 10-fold in obstructed kidneys between 24 and 96 h following UUO, with a high proportion of these having incorporated BrdU by 72 h. Although this does not formally identify the site of T-cell proliferation, the lower rate of BrdU incorporation in the equivalent subset from the non-obstructed kidneys provides evidence that intrarenal proliferation is also an important mechanism of Th17 cell accumulation in AKI.
Recently, a role has emerged for IL-23 in the differentiation and activation of pathogenic Th17 cells and other IL-17A-producing leukocytes in rodent models of glomerulonephritis and ischemia-reperfusion injury and in human antineutrophil cytoplasmic antibody-associated vasculitis. 17, 21, 32, 38, 48 In other autoimmune and inflammatory conditions, IL-1 has been identified as an important local mediator of pathogenic Th17-cell activation. 29, 43 In the current study, we demonstrate the secretion of soluble Th17-enhancing activity by cells from obstructed kidneys. This activity was localized initially to CD45 þ intrarenal leukocytes (both CD11c þ and CD11c À ) and next to F4/80 although not to Ly6C lo macrophages. Interestingly, although increased expression of both IL-1a/b and IL-23 were observed in DCs and monocytes from obstructed kidneys, IL-1 family cytokines, functioning via IL-1R1, were found to be entirely responsible for this in vitro Th17-activating effect. The in vivo relevance of this finding was validated in IL-1RI-deficient mice in which Th17 cell activity was reduced in obstructed kidneys compared with wild-type animals despite comparable, or greater, accumulation of CD4 þ CCR6 þ T cells. Similarly, mice treated with IL-1Ra following UUO demonstrated reduced intrarenal Th17 activity. In this experiment, concomitant BrdU labeling indicated that IL-1R blockade reduced Th17 activity among proliferative (BrdU þ ) Th cells from obstructed kidneys. In contrast, BrdU incorporation and IL-17A production by splenic Th cells was unaffected. Thus, we convincingly show that both activation and proliferation of intrarenal Th17 cells are positively regulated by IL-1. Although this does not rule out a role for IL-23 in other aspects of the triggering of Th17 cells during intrarenal inflammation, it does emphasize the significance of IL-1 in specifically promoting Th17-cell activation and expansion at sites of localized 'sterile' inflammation. 49, 50 Given the growing interest in clinical application of IL-1 antagonists and blocking antibodies to inflammatory diseases, 50 ,51 the potential to target pathogenic renal Th17 responses by this strategy merits consideration. Notably, Timoshanko et al. 52 observed attenuation of experimental glomerulonephritis in mice lacking IL-1R1, IL-1a, or IL-1b, and Furuichi et al. 53 demonstrated reduced early severity of renal ischemia-reperfusion injury in IL-1a/b-deficient mice, as well as exacerbated injury in mice genetically lacking IL-1Ra. In UUO, Jones et al. 40 observed reduced intrarenal pro-fibrotic activity at 7 (but not 14) days in IL-1R1-deficient compared with wild-type mice, although T-cell infiltration and Th activity was not analyzed in this study. In our own experiments using IL-1Ra during the initial 72 h following UUO, we observed only a mild protective effect against tubular dilatation and atrophy by histological analysis, with no overt reduction in the extent of interstitial cellular infiltrates. Furthermore, despite the inhibition of Th17 activity, neutrophil infiltration of obstructed kidneys at this time point was not reduced when analyzed by flow cytometry (data not shown). Thus, although UUO has proven to be of value as a model system in which to evaluate the dynamics and activation factors for intrarenal Th17 cells during kidney injury, our data suggest that IL-1 blockade and its associated inhibition of localized Th17 activity may be of limited benefit in obstructive renal injury. As Kitching and Holdsworth 18 have recently highlighted, cross-regulation of Th17 and Th1 cells during inflammation could result in augmentation of harmful Th1 responses following specific Th17 targeting. However, although we observed increased numbers of CD4 þ IFN-g þ T cells in obstructed kidneys of IL-1R1-KO compared with wild-type mice, this phenomenon was not reproduced in IL1Ra-treated mice in which a trend toward reduced Th1 activity in obstructed kidneys was observed in the form of lower anti-CD3-stimulated IFN-g production (see Supplementary Figure S6a online). In this experiment, it was not possible to accurately co-stain for intracellular BrdU and IFN-g (data not shown). Thus, although our findings clearly document the enhancing effect of IL-1 on intrarenal Th17 activation and proliferation, its role in regulating intrarenal Th1 (as well as other Th subsets) remains unclear. In the broader sense, the lack of robust benefit of IL-1 blockade and intrarenal Th17 suppression in UUO likely reflects the general observation that therapeutic approaches for inflammatory diseases based on targeting of a single cytokine/chemokine have been less successful than a multi-pronged approach. In contrast, antigen-driven, immune-mediated kidney diseases in which Th17 cells have been shown to have a major pathogenic role (e.g., antineutrophil cytoplasmic antibody-associated vasculitis and crescentic glomerulonephritis) may prove to be more responsive to IL-1 blockade either alone or in combination with inhibition of other Th17-differentiation and -activation factors such as IL-23, IL-6, and transforming growth factorb1. It should also be noted that Th17 cells represent only one discrete target for locally produced IL-1 within the kidney and, as shown by Timoshanko et al. 52 in chimeric mice, the responses of non-immune, resident renal cells to IL-1 contribute significantly to tumor necrosis factor production and glomerular injury in a model of crescentic glomerulonephritis.
In summary, we have used the UUO model as an 'incubator' of localized Th17 cell accumulation within the inflamed kidney. Our findings favor the following conclusions: (1) Effector memory CD4 þ T cells preprogrammed for IL-17A production accumulate in substantial numbers within injured kidney through chemokine receptor-specific recruitment and localized proliferation. (2) Even without antigenic priming, acute renal inflammation induces local activation of Th17 cells, of which IL-1, produced by DCs and inflammatory monocytes, is a key mediator. Our findings will be of value in better defining the dynamics and pathogenic properties of intrarenal Th17 cells, their dependence upon activation factors secreted locally within the kidney by cells of the mononuclear phagocyte system, and the targets available for inhibiting their effector functions during kidney disease.
MATERIALS AND METHODS Experimental animals
Eight-to twelve-week-old female C57BL/6 (B6) mice were purchased from Harlan Laboratories UK (Bicester, UK). Mice genetically deficient in IL-1R1 on a B6 background, originally from Jackson Laboratories, Bar Harbor, ME, were bred on-site. Animals were housed in specific pathogen-free facilities. Procedures were carried out under license from the Irish Department of Health and Children and approved by the NUI Galway Animal Ethics Committee.
Reagents
Antibodies, culture media, buffer solutions, ELISA reagents, and other materials used in the study are detailed in Supplementary Methods online.
Cell cultures
Cells were cultured in 96-well round-bottom plates at 10 6 cells/ml with other additions as described for individual experiments. For ELISA of secreted products, supernatants were withdrawn at 24 h. For surface and intracellular staining of cultured cells, Brefeldin A (GolgiPlug 1 ml/ml, BD Biosciences, Oxford, UK) was added 8 h before analysis. For preparation of CM, magnetic column-purified cells were placed in culture at 10 6 cells/ml for 24 h, following which media were withdrawn and frozen at À20 1C before being used at 1:1 ratio with fresh medium as described for individual experiments.
UUO and preparation of kidney cell digests Mouse UUO with preparation of cell suspensions between 24 and 96 h later by collagenase/DNase digestion was conducted as previously described (see also Supplementary Methods online). 20, 54 In some experiments, mice received a bolus of BrdU intraperitoneally at the time of surgery, followed by continuous exposure to BrdU-containing water for 72 h. In some experiments, groups of mice also received the IL-1R antagonist (IL-1Ra), anakinra, at a concentration of 100 mg/kg i.p. in 250 ml of phosphate-buffered saline or phosphate-buffered saline alone by intraperitoneal injection at 0, 24, and 48 h following UUO.
Flow cytometry, fluorescence-activated cell sorting, and magnetic column separation of kidney cells Kidney cells suspended in 100 ml aliquots of FACS buffer were incubated with 3-5 fluorochrome-labeled and/or biotinylated antibodies for 30 min at 4 1C, followed by washing in FACS buffer and, if necessary, incubation with fluorochrome-labeled streptavidin for 30 min at 4 1C and then resuspended in 4% paraformaldehyde in phosphate-buffered saline. Intracellular staining was carried out using the Cytofix/Cytoperm and BrdU detection kits (BD Biosciences) according to the manufacturer's instructions. Analysis was performed using a BD Biosciences FACSCanto flow cytometer and FlowJo software (TreeStar, Olten, Switzerland).
For FACS, cell suspensions from 3-5 kidneys were resuspended in FACS sorting buffer with fluorochrome-and biotin-labeled monoclonal antibodies for 30 min at 4 1C, and then washed, filtered through a 40-mm mesh and sorted using a BD Biosciences FACSAriaII sorter with purity determined by post-sort analysis.
Magnetic column separations of kidney cell suspensions were carried out in MACS buffer by manufacturer-recommended protocols using MS columns and an OctoMACS separator (Miltenyi Biotec, Auburn, CA). For individual experiments, positive and/or negative column fractions were retained, washed in MACS buffer, and used for culture and/or qRT-PCR. In some experiments, cell suspensions were first subjected to anti-CD11c magnetic column separation, and then the negative fractions were subjected to anti-CD45 magnetic column separation to sequentially prepare CD11c þ , CD45 þ CD11c À , and CD45 À cell fractions.
Cultures with in vitro-generated Th17 and Th1 cells Th17-and Th1-skewed mouse CD4 þ T-cell cultures were generated over 10 days from splenocytes of healthy adult mice using standard protocols (see Supplementary Methods online for details). For restimulation experiments, CD4 þ T cells were repurified from differentiation cultures by magnetic column separation and then plated in fresh culture medium 10 6 cells/ml with or without anti-CD3 (1.0 or 0.1 mg/ml) for 24 h. In individual experiments, conditioned or control media were added at a 1:1 ratio with fresh medium. In some experiments, previously optimized concentrations of blocking antibodies or relevant isotype control antibodies were also added. In others, FACS-purified cells from non-obstructed and obstructed kidneys were added at a 1:10 ratio. After 24 h, concentrations of IL-17A and IFN-g were measured in culture supernatants by ELISA.
RNA preparation and qRT-PCR Total RNA was isolated from whole kidney or sorted cell populations using RNeasy Mini or Micro kits (Qiagen, Valencia, CA; see also Supplementary Methods online). RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems, Carlsbad, CA). Equal amounts of cDNA were analyzed by qRT-PCR using the TaqMan Master Mix and commercial primer/probe sets for mouse GAPDH, IL-1a, IL-1b, IL-17A, IL-6, and IL-23(p19) on a StepOne Plus Real Time PCR System (all from Applied Biosystems). Relative quantifications were performed using the comparative C T method with normalization to GAPDH and results expressed as fold difference relative to a relevant control sample.
Statistical analysis
Individual experiments were carried out between two and six times to ensure reproducibility. For culture experiments, between three and six replicates were initiated and individually analyzed for each condition. Data are presented as mean±s.d. Statistical comparisons between individual groups were performed by unpaired, two-tailed t-tests using Microcal Origin V6.0 software (Northampton, MA) with significance assigned at Po0.05.
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KHGM is a cofounder and minority shareholder in Opsona Therapeutics, a start-up company involved in the development of anti-inflammatory therapeutics. Figure S1 . The gating strategy and purity of fluorescence-activated cell sorting from 72-h obstructed kidneys for the purpose of analyzing interleukin (IL-17A) mRNA expression is shown. Figure S2 . Examples of intracellular flow cytometric analysis of in vitro-generated T-helper 17 (Th17) cells for interleukin (IL)-17A following anti-CD3 stimulation with and without exposure to conditioned media from CD45-depleted (CD45 À ) and CD45-enriched (CD45 þ ) cells of obstructed kidneys following 24, 48, and 72 h of unilateral ureteral obstruction (UUO). Figure S7 . Histological scoring for tubulointerstitial injury in control and obstructed kidneys of vehicle-and IL-1Ra-treated mice. Figure S8 . The gating strategy and purity of fluorescence-activated cell sorting from 72-h obstructed kidneys for the purpose of isolating individual myeloid cell populations is shown. Figure S9 . Renal myeloid cell populations do not enhance interferongamma (IFN-g) production by in vitro-generated T-helper 1 (Th1) cells following unilateral ureteral obstruction (UUO). 
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